These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29138683)

  • 21. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Al Malik Y; Meftah I
    Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
    Julian GS; Rosim RP; Carneseca EC; Rigolon J
    PLoS One; 2020; 15(3):e0229768. PubMed ID: 32119696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
    Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia.
    Lasalvia P; Hernández F; Castañeda-Cardona C; Cuestas JA; Rosselli D
    Value Health Reg Issues; 2020 Dec; 23():13-18. PubMed ID: 31999987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
    Curti E; Tsantes E; Baldi E; Caniatti LM; Ferraro D; Sola P; Granella F
    Mult Scler Relat Disord; 2019 Aug; 33():146-152. PubMed ID: 31200271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
    Barrero F; Mallada-Frechin J; Martínez-Ginés ML; Marzo ME; Meca-Lallana V; Izquierdo G; Ara JR; Oreja-Guevara C; Meca-Lallana J; Forero L; Sánchez-Vera I; Moreno MJ;
    PLoS One; 2020; 15(4):e0230846. PubMed ID: 32240213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life clinical use of natalizumab and fingolimod in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T
    Acta Neurol Scand; 2018 Feb; 137(2):181-187. PubMed ID: 29159801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 30. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
    Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
    Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
    Kalincik T; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Lechner-Scott J; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Solaro C; Grand'Maison F; Hupperts R; Prevost J; Sola P; Ferraro D; Terzi M; Butler E; Slee M; Kermode A; Fabis-Pedrini M; McCombe P; Barnett M; Shaw C; Hodgkinson S; Butzkueven H;
    Mult Scler; 2018 Oct; 24(12):1617-1626. PubMed ID: 28857680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    Kapica-Topczewska K; Tarasiuk J; Collin F; Brola W; Chorąży M; Czarnowska A; Kwaśniewski M; Bartosik-Psujek H; Adamczyk-Sowa M; Kochanowicz J; Kułakowska A
    PLoS One; 2019; 14(10):e0223863. PubMed ID: 31647829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Barbin L; Rousseau C; Jousset N; Casey R; Debouverie M; Vukusic S; De Sèze J; Brassat D; Wiertlewski S; Brochet B; Pelletier J; Vermersch P; Edan G; Lebrun-Frenay C; Clavelou P; Thouvenot E; Camdessanché JP; Tourbah A; Stankoff B; Al Khedr A; Cabre P; Papeix C; Berger E; Heinzlef O; Debroucker T; Moreau T; Gout O; Bourre B; Créange A; Labauge P; Magy L; Defer G; Foucher Y; Laplaud DA;
    Neurology; 2016 Feb; 86(8):771-8. PubMed ID: 26826205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
    Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.
    Boremalm M; Juto A; Axelsson M; Novakova L; Frisell T; Svenningsson A; Lycke J; Piehl F; Salzer J
    Eur J Neurol; 2019 Aug; 26(8):1060-1067. PubMed ID: 30762259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
    La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S
    Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
    Klotz L; Grützke B; Eveslage M; Deppe M; Gross CC; Kirstein L; Posevitz-Fejfar A; Schneider-Hohendorf T; Schwab N; Meuth SG; Wiendl H
    BMC Neurol; 2015 Jun; 15():96. PubMed ID: 26099927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Boudot de la Motte M; Louapre C; Bertrand A; Reach P; Lubetzki C; Papeix C; Maillart E
    Mult Scler; 2017 Apr; 23(4):614-616. PubMed ID: 28273764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
    Noon KM; Montgomery SM; Adlard NE; Kroes MA
    J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.